Concord Biotech Ltd

Concord Biotech announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 10.7 per equity Share (i.e. 1070%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Concord Biotech rose 47.75% to Rs 140.39 crore in the quarter ended March 2025 as against Rs 95.02 crore during the previous quarter ended March 2024. Sales rose 34.77% to Rs 429.88 crore in the quarter ended March 2025 as against Rs 318.97 crore during the previous quarter ended March 2024. For the full year,net profit rose 20.62% to Rs 371.64 crore in the year ended March 2025 as against Rs 308.10 crore during the previous year ended March 2024. Sales rose 18.01% to Rs 1200.09 crore in the year ended March 2025 as against Rs 1016.94 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales429.88318.97 35 1200.091016.94 18 OPM %43.9441.41 -42.0842.44 - PBDT198.16142.44 39 548.93466.16 18 PBT183.54128.72 43 494.55412.57 20 NP140.3995.02 48 371.64308.10 21 Powered by Capital Market - Live

Concord Biotech will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live

Teriflunomide tablets are used for the treatment of patients with relapsing forms of multiple sclerosis. This approval reinforces our capability in successfully developing and commercializing a differentiated product portfolio for the U.S. market, Concord Biotech said in a statement. According to IQVIA, the market size of Teriflunomide tablets is approximately $402 million in the US, and the global market size is approximately $908 million, indicating significant opportunities for expansion in the US and the global market. Concord Biotech is involved in manufacturing fermentation and semi-synthetic biopharmaceutical APIs with immunosuppressants as its key therapeutic segment. The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25. The scrip shed 0.17% to currently trade at Rs 1595.10 on the BSE. Powered by Capital Market - Live

Concord Biotech has successfully commissioned and commenced production of injectable at its new manufacturing facility (Unit 4) situated at Valthera. Powered by Capital Market - Live

This rebound follows a steep decline of 28.15% over the preceding seven trading sessions, triggered by the company's disappointing third-quarter financial results for the 2025 fiscal year (Q3FY25). The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25. Profit before tax (PBT) fell 2% YoY to Rs 75.92 crore during the quarter. EBITDA stood at Rs 98 crore, registering de-growth of 8% compared with Rs 105.9 crore in corresponding quarter last year. EBITDA margin reduced by 390 bps to 40.1% in Q3 FY25 as against 44% in Q3 FY24. Concord Biotech is a R&D driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It has a presence in more than 70 countries worldwide. Powered by Capital Market - Live

Senco Gold Ltd, Deepak Nitrite Ltd, MSTC Ltd and Orchid Pharma Ltd are among the other losers in the BSE's 'A' group today, 14 February 2025.Concord Biotech Ltd lost 20.00% to Rs 1688 at 14:48 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 47914 shares were traded on the counter so far as against the average daily volumes of 4439 shares in the past one month.Senco Gold Ltd crashed 19.99% to Rs 357.6. The stock was the second biggest loser in 'A' group.On the BSE, 1.77 lakh shares were traded on the counter so far as against the average daily volumes of 41073 shares in the past one month.Deepak Nitrite Ltd tumbled 14.60% to Rs 1910.2. The stock was the third biggest loser in 'A' group.On the BSE, 2.44 lakh shares were traded on the counter so far as against the average daily volumes of 6902 shares in the past one month.MSTC Ltd dropped 10.92% to Rs 535.35. The stock was the fourth biggest loser in 'A' group.On the BSE, 39461 shares were traded on the counter so far as against the average daily volumes of 18976 shares in the past one month.Orchid Pharma Ltd plummeted 10.00% to Rs 945.45. The stock was the fifth biggest loser in 'A' group.On the BSE, 22338 shares were traded on the counter so far as against the average daily volumes of 13301 shares in the past one month.Powered by Capital Market - Live

The key equity indices traded with major losses in the early afternoon trade. The Nifty dropped below the 22,850 mark after hitting the day's high of 23,133.70 in early trade. Media shares declined after advancing in the past trading session. At 12:30 IST, the barometer index, the S&P BSE Sensex, declined 482.15 points or 0.63% to 75,656.82. The Nifty 50 index slipped 186.25 points or 0.81% to 22,845.15. The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index fell 2.63%, and the S&P BSE Small-Cap dropped 3.23%. The market breadth was weak. On the BSE, 605 shares rose and 3,936 shares fell. A total of 118 shares were unchanged. Economy: The India Wholesale Price Index (WPI) for January 2025 stood at 2.31% (provisional) year-on-year compared to January 2024. The positive inflation rate in January 2025 was primarily driven by an increase in prices of manufactured food products, food articles, other manufacturing, non-food articles, and textiles. However, the WPI for January 2025 recorded a decline of 0.45% compared to December 2024. Derivatives: The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, advanced 3.12% to 15.42. The Nifty 27 February 2025 futures were trading at 22,907.45, at a premium of 62.3 points as compared with the spot at 22,845.15. The Nifty option chain for the 27 February 2025 expiry showed a maximum call OI of 60.6 lakh contracts at the 23,500 strike price. Maximum put OI of 53 lakh contracts was seen at 23,000 strike price. Buzzing Index: The Nifty Media index declined 2.45% to 1,506.80. The index rose 0.49% in the past trading session. Tips Music (down 3.98%), Den Networks (down 3.43%), Network 18 Media & Investments (down 3.39%), Dish TV India (down 3.1%), PVR Inox (down 2.79%), Zee Entertainment Enterprises (down 2.1%), Hathway Cable & Datacom (down 2.02%), Saregama India (down 1.9%), Sun TV Network (down 1.71%) and Nazara Technologies (down 0.65%) declined. Stocks in Spotlight: Concord Biotech tanked 17.24% after the company's consolidated net profit fell 2.1% to Rs 75.92 crore in Q3 FY25 as compared with Rs 77.57 crore in Q3 FY24. Revenue from operations increased 1.4% YoY to Rs 244.22 crore in Q3 FY25. Deepak Nitrite tumbled 15.20% after the company's consolidated net profit tanked 51.45% to Rs 98.09 crore in Q3 FY25, compared with Rs 202.05 crore recorded in the same period last. Revenue from operation stood at Rs 1,903.40 crore in Q3 FY25, down 5.27%, compared with Rs 2,009.23 crore posted in Q3 FY24. Nazara Technologies shed 0.79%. The company reported a 52.89% decline in consolidated net profit from continuing operations to Rs 13.68 crore despite a 66.88% increase in revenue from operations to Rs 534.69 crore in Q3 FY25 over Q3 FY24.Powered by Capital Market - Live

Revenue from operations increased 1.4% YoY to Rs 244.22 crore in Q3 FY25. Profit before tax (PBT) fell 2.13% to Rs 75.92 crore during the quarter. EBITDA stood at Rs 98 crore, registering de-growth of 8% as compared with Rs 105.9 crore posted in corresponding quarter last year. EBITDA margin reduced by 390 bps to 40.1% in Q3 FY25 as against 44% in Q3 FY24. Revenue from active pharmaceutical ingredients (API) increased 3% to Rs 176.6 crore while revenue from formulation declined 1% to Rs 67.6 crore in Q3 FY25 over Q3 FY24. In Q3 FY25, API business contributes 72% to the total revenue, while formulation business accounted for 28%. Ankur Vaid, Joint managing director & chief executive officer, Concord Biotech, said, 'Revenue for Q3FY25 stood at Rs 244 crore as, a growth of 1% on a Y-o-Y basis. Our EBIDTA margins stood at 40.1%.Our Profit after tax stood at Rs 75.9 crore in Q3FY25. Revenues from API segment grew at 3% over the same period last year, the growth was impacted on account of lumpiness in the procurement pattern of customers and some spill over of revenue to the following quarter. We remain optimistic of our growth in both API & Formulation segment on the back of new product addition, customer addition and incremental wallet share gain from existing customers. We remain optimistic about achieving our long-term target of a 25% CAGR over the next five years. Additionally, we are actively exploring CDMO/CMO opportunities with customers worldwide. Given Concord's capabilities and capacities, we are confident in seizing this opportunity sooner rather than later, which will further accelerate our growth trajectory.' Concord Biotech is an India-based R&D-driven biopharma company. The company is ranked among the leading global developers and manufacturers of select fermentation-based active pharmaceutical ingredients (API) across immunosuppressants and oncology in terms of market share, based on volume in 2022.Powered by Capital Market - Live

Net profit of Concord Biotech declined 2.13% to Rs 75.92 crore in the quarter ended December 2024 as against Rs 77.57 crore during the previous quarter ended December 2023. Sales rose 1.42% to Rs 244.22 crore in the quarter ended December 2024 as against Rs 240.80 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales244.22240.80 1 OPM %40.1143.99 - PBDT114.42116.64 -2 PBT101.15103.10 -2 NP75.9277.57 -2 Powered by Capital Market - Live